Faculty profile

Adrian Sacher

ResearcherUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Adrian Sacher

Researcher

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
41 publications in the last five years, latest in 2026.
Senior (last) author on 4 recent papers, a sign of leading a research group.
Principal investigator on 2 research grants (2 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

283

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Immunotherapy Innate Immunity Lung Cancer Tumor Microenvironment Microbiome Non-Small Cell Lung Cancer Tumor Immunology

Latest papers

Biomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms-A Brief Report.
JTO clinical and research reports · 2026
KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable.
Cancer journal (Sudbury, Mass.) · 2026 · senior author
SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies.
iScience · 2026

All 62 publications

Latest funding

Unconventional Innate-like T cells and Innate Lymphoid Cells as a Foundation for Novel Immunotherapeutic and Adoptive Cell Therapy Strategies in Metastatic Non-Small Cell Lung Cancer
CIHR · 2023 · Principal investigator
$1,000,000
Control of invariant Natural Killer T cell helper and cytotoxic functions in cancer
CIHR · 2020 · Co-investigator
$1,051,875
Mucosal Associated Invariant T-cells (MAIT cells) as Key Mediators of Anti-Tumor Immune Responses and the Microbiome Effect in Non-Small Cell Lung Cancer (NSCLC)
CIHR · 2019 · Nominated PI
$283,051

All 4 grants and awards

62 publications.

Biomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms-A Brief Report.

Fan ZJ, Tudor R, Cabanero M, Le LW, Rabey M, Law JH, Stockley T, Kuang S, Meti N, Fung A, Perdrizet K, Chen K, Li JJN, Ghumman N, Ranich L, Wei C, Sabatini P, Pal P, Hsu YR, Ko HM, Schwock J, Tsao MS, Liu G, Shepherd FA, Bradbury P, Sacher A, Eng L, Leighl NB

JTO clinical and research reports2026

DOI: 10.1016/j.jtocrr.2026.101012 PMID: 42529245

KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable.

El Saadany T, Aeschlimann N, Sacher A

Cancer journal (Sudbury, Mass.)2026Senior author

DOI: 10.1097/ppo.0000000000000842 PMID: 42497392

SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies.

Wu BX, Ran X, Huang O, Song L, Philip V, Sacher A, Tsao MS, Lok BH

iScience2026

DOI: 10.1016/j.isci.2026.116864 PMID: 42548914

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.

de Marinis F, Kim TM, Bonanno L, Cheng S, Kim SW, Tiseo M, Chu Q, Proto C, Sacher A, Luo YH, Novello S, Hao D, Baik C, Bazhenova L, Lee JS, Cho BC, Cadranel J, Diep TB, Metro G, Narayanan P, Yoneshima Y, de Castro Carpeño J, Baldotto C, Yang JC, Sequist LV, Levy B, Hartmaier R, Igwegbe I, Poole L, Xu W, Ahn MJ

Future oncology (London, England)2026

DOI: 10.1080/14796694.2026.2692029 PMID: 42460617

ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.

Garassino MC, Cousin S, Besse B, Sacher A, Orlov S, Schenker M, Felip E, Gladkov O, Messina CH, Majumdar A, Wu ZJ, Karpinich NO, Hirschfeld S, Ballas M, Reck M

Clinical lung cancer2026

DOI: 10.1016/j.cllc.2026.04.003 PMID: 42120266

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.

Lee CK, Lefresne S, Soon YY, Robledo K, Nichol A, Sahgal A, Pinkham MB, Melosky B, Huang Y, McDermott R, Tham IWK, Parmar A, Tey JCS, Liu M, Solomon BJ, Sacher A, Leong CN, Laskin J, Koh WY, Menjak IB, Ang Y, Shultz DB, Low JL, Doherty M, Yong C, Lim MC, Tan AP, Soo RA, Hegi-Johnson F, Ho C

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026

DOI: 10.1016/j.jtho.2026.01.001 PMID: 41534788

Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms.

Rosen JC, Cao P, Pham NA, Waas M, Li Q, Hueniken K, Wang M, Navab R, Wybenga-Groot L, Radulovich N, Niedbala M, Koers A, Ross S, Moran MF, Sacher A, Tsao MS

British journal of cancer2026

DOI: 10.1038/s41416-025-03216-w PMID: 41076489

KRASG12C inhibitor combination therapy in metastatic non-small-cell lung cancer: choosing the right path.

El Saadany T, Sacher A

The Lancet. Oncology2026Senior author

DOI: 10.1016/s1470-2045(26)00119-1 PMID: 41926954

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.

Burns TF, Ammakkanavar NR, Hollebecque A, Lee DH, Koyama T, Cassier PA, Italiano A, Han JY, Singhal N, Takeuchi S, Heist RS, Deming D, Spira A, Chu Q, Sacher A, Fujiwara Y, Chisamore MJ, You AX, McNeely SC, Fink A, Chen A, Oxnard GR, Willard MD, Murciano-Goroff YR, Dragnev KH

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2026

DOI: 10.1016/j.jtho.2025.11.018 PMID: 41319864

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Murciano-Goroff YR, Hollebecque A, Heist RS, Cassier PA, Han JY, Kim SY, Sabari JK, Tosi D, Sacher A, Burns TF, Shimizu T, Reddy Ammakkanavar N, Spira A, Gomez-Roca C, Patnaik A, Cosman R, Bodor JN, Nagasaka M, You AX, McNeely SC, Peter R, Fink A, Chen A, Oxnard GR, Willard MD, Kuboki Y, Koyama T

Nature communications2026

DOI: 10.1038/s41467-026-69943-7 PMID: 41820335

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Immunotherapy Dear Professor Sacher, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Biomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms-A Brief Report." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Unconventional Innate-like T cells and Innate Lymphoid Cells as a Foundation for Novel Immunotherapeutic and Adoptive Cell Therapy Strategies in Metastatic Non-Small Cell Lung Cancer" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Adrian Sacher

Research

Latest papers

Latest funding

Biomarker Testing Among Patients With Nonsquamous NSCLC Across Three Time Periods and Three Testing Platforms-A Brief Report.

KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable.

SCLC humanized mice identify T cell infiltration phenotypes in response to combination immune-radiation therapies.

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib.

ENTR&#xc9;E Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.

Osimertinib and Stereotactic Radiosurgery for Brain Metastases in EGFR-Mutated Lung Cancer: The STARLET Joint Analysis of OUTRUN and LUOSICNS Randomized Trials.

Modeling response to the KRAS-G12C inhibitor AZD4625 in KRASG12C NSCLC patient-derived xenografts reveals insights into primary resistance mechanisms.

KRASG12C inhibitor combination therapy in metastatic non-small-cell lung cancer: choosing the right path.

Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLC.

Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human study.

Unconventional Innate-like T cells and Innate Lymphoid Cells as a Foundation for Novel Immunotherapeutic and Adoptive Cell Therapy Strategies in Metastatic Non-Small Cell Lung Cancer

Control of invariant Natural Killer T cell helper and cytotoxic functions in cancer

Mucosal Associated Invariant T-cells (MAIT cells) as Key Mediators of Anti-Tumor Immune Responses and the Microbiome Effect in Non-Small Cell Lung Cancer (NSCLC)

The SCF(FBXO11) - XAB2 axis mediates DNA repair and therapeutic resistance in small cell lung cancer

Frequent collaborators

Geoffrey Liu

Ming-Sound Tsao

Lawson Eng

Rosalyn Juergens

Paul Wheatley-Price

Kazuhiro Yasufuku

Tracy Stockley

Wei Xu

Anna Spreafico

Igor Stagljar

Jim Hu

Andrew Hope

Paaladinesh Thavendiranathan

Houda Bahig

Jonathan Yeung

Arielle Elkrief

Alan Nichol

Ahmed Aman

David Uehling

Elliot Wakeam

Hans Katzberg

Rosane Nisenbaum

Winson Cheung

Arjun Sahgal

Trevor Pugh

Armand Keating

Tracy McGaha

Janet Parsons

Bertrand Routy

Janet Dancey

Robert Rottapel

Cheryl Arrowsmith

Shaf Keshavjee

Mingyao Liu

ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC.